<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36767932</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1660-4601</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>31</Day></PubDate></JournalIssue><Title>International journal of environmental research and public health</Title><ISOAbbreviation>Int J Environ Res Public Health</ISOAbbreviation></Journal><ArticleTitle>Association of Lung Fibrotic Changes and Cardiological Dysfunction with Comorbidities in Long COVID-19 Cohort.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2567</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijerph20032567</ELocationID><Abstract><AbstractText><b>Background</b>. Long COVID-19 symptoms appeared in many COVID-19 survivors. However, the prevalence and symptoms associated with long COVID-19 and its comorbidities have not been established. <b>Methods</b>. In total, 312 patients with long COVID-19 from 21 primary care centers were included in the study. At the six-month follow-up, their lung function was assessed by computerized tomography (CT) and spirometry, whereas cardiac function was assessed by elec-trocardiogram (ECG), Holter ECG, echocardiography, 24 h blood pressure monitoring, and a six-minute walk test (6MWT). <b>Results</b>. Of the 312 persons investigated, significantly higher sys-tolic and diastolic blood pressure, left ventricular hypertrophy, and elevated NT-proBNP were revealed in participants with hypertension or type 2 diabetes. Left ventricular diastolic dysfunc-tion was more frequently present in patients with hypertension. The most common registered CT abnormalities were fibrotic changes (83, 36.6%) and mediastinal lymphadenopathy (23, 10.1%). Among the tested biochemical parameters, three associations were found in long COVID-19 patients with hypertension but not diabetes: increased hemoglobin, fibrinogen, and ferritin. Nine patients had persisting IgM antibodies to SARS-CoV-2. <b>Conclusions</b>. We demon-strated a strong association between signs of cardiac dysfunction and lung fibrotic changes with comorbidities in a cohort of long COVID-19 subjects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tauekelova</LastName><ForeName>Ainur T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>National Research Center for Cardiac Surgery, Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalila</LastName><ForeName>Zhanar</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>National Research Center for Cardiac Surgery, Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakhtiyar</LastName><ForeName>Akerke</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Research Center for Cardiac Surgery, Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sautbayeva</LastName><ForeName>Zarina</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>School of Sciences and Humanities, Nazarbayev University, Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Len</LastName><ForeName>Polina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Sciences and Humanities, Nazarbayev University, Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sailybayeva</LastName><ForeName>Aliya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Research Center for Cardiac Surgery, Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khamitov</LastName><ForeName>Sadyk</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Research Center for Cardiac Surgery, Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadroldinova</LastName><ForeName>Nazira</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-4309-0432</Identifier><AffiliationInfo><Affiliation>School of Medicine, Nazarbayev University, Astana 020000, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barteneva</LastName><ForeName>Natasha S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>School of Sciences and Humanities, Nazarbayev University, Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bekbossynova</LastName><ForeName>Makhabbat S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>National Research Center for Cardiac Surgery, Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Environ Res Public Health</MedlineTA><NlmUniqueID>101238455</NlmUniqueID><ISSNLinking>1660-4601</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiovascular sequalae</Keyword><Keyword MajorTopicYN="N">diabetes</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">lung sequelae</Keyword><Keyword MajorTopicYN="N">persisting IgM against SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">post-COVID-19</Keyword></KeywordList><CoiStatement>The authors declare no competing financial interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>1</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36767932</ArticleId><ArticleId IdType="pmc">PMC9915134</ArticleId><ArticleId IdType="doi">10.3390/ijerph20032567</ArticleId><ArticleId IdType="pii">ijerph20032567</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Furukawa N.W., Brooks J.T., Sobel J. Evidence supporting transmission of severe acute respiratory syndrome coronavirus 2 while pre-symptomatic or asymptomatic. Emerg. Infect. Dis. 2020;26:e201595. doi: 10.3201/eid2607.201595.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2607.201595</ArticleId><ArticleId IdType="pmc">PMC7323549</ArticleId><ArticleId IdType="pubmed">32364890</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivett L., Sridhar S., Sparkes D., Routledge M., Jones N., Forrest S., Young J., Pereira-Dias J., Hamilton W., Ferris M., et al. Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. eLife. 2020;9:e58728. doi: 10.7554/eLife.58728.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.58728</ArticleId><ArticleId IdType="pmc">PMC7314537</ArticleId><ArticleId IdType="pubmed">32392129</ArticleId></ArticleIdList></Reference><Reference><Citation>Buitrago-Garcia D., Egli-Gany D., Counotte M., Hossmann S., Imeri H., Ipekci A., Salanti G., Low N. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 2020;17:e1003346. doi: 10.1371/journal.pmed.1003346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003346</ArticleId><ArticleId IdType="pmc">PMC7508369</ArticleId><ArticleId IdType="pubmed">32960881</ArticleId></ArticleIdList></Reference><Reference><Citation>Clerkin K.J., Fried J.A., Raikhelkar J., Sayer G., Griffin J.M., Masoumi A., Jain S.S., Burkhoff D., Kumaraiah D., Rabbani L., et al. COVID-19 and cardiovascular disease. Circulation. 2020;141:1648&#x2013;1655. doi: 10.1161/CIRCULATIONAHA.120.046941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.046941</ArticleId><ArticleId IdType="pubmed">32200663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunutsor S.K., Laukkanen J.A. Cardiovascular complications in COVID-19: A systematic review and meta-analysis. J. Infect. 2020;81:e139&#x2013;e141. doi: 10.1016/j.jinf.2020.05.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.05.068</ArticleId><ArticleId IdType="pmc">PMC7832225</ArticleId><ArticleId IdType="pubmed">32504747</ArticleId></ArticleIdList></Reference><Reference><Citation>Polverino F., Stern D.A., Ruocco G., Balestro E., Bassetti M., Candelli M., Cirillo B., Contoli M., Corsico A., D&#x2019;Amico F., et al. Comorbidities, cardiovascular therapies, and COVID-19 mortality: A nationwide, Italian observational study (ItaliCO) Front. Cardiovasc. Med. 2020;7:585866. doi: 10.3389/fcvm.2020.585866.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2020.585866</ArticleId><ArticleId IdType="pmc">PMC7583635</ArticleId><ArticleId IdType="pubmed">33195473</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiroi Y., Ohtsu H., Uemura Y., Hayakawa K., Asai Y., Kutsuna S., Terada M., Sugiura W., Ohmagari N. Cardiovascular complications of hospitalized patients with coronavirus disease 2019 in a Japanese registry in 2020. Circ. J. 2022;86:464&#x2013;471. doi: 10.1253/circj.CJ-21-0687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-21-0687</ArticleId><ArticleId IdType="pubmed">35095056</ArticleId></ArticleIdList></Reference><Reference><Citation>Leth S., Gunst J.D., Mathiasen V., Hansen K., S&#xf8;gaard O., &#xd8;stergaard L., Jensen-Fangel S., Storgaard M., Agergaard J. Persistent symptoms in patients recovering from COVID-19 in Denmark. Open Forum Infect. Dis. 2021;8:ofab042. doi: 10.1093/ofid/ofab042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab042</ArticleId><ArticleId IdType="pmc">PMC7928683</ArticleId><ArticleId IdType="pubmed">33875970</ArticleId></ArticleIdList></Reference><Reference><Citation>Renda G., Ricci F., Spinoni E.G., Grisafi L., D&#x2019;ardes D., Mennuni M., Tana C., Rognoni A., Bellan M., Sainaghi P.P., et al. Predictors of mortality and cardiovascular outcome at 6 months after hospitalization for COVID-19. J. Clin. Med. 2022;11:729. doi: 10.3390/jcm11030729.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11030729</ArticleId><ArticleId IdType="pmc">PMC8836381</ArticleId><ArticleId IdType="pubmed">35160182</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigfrid L., Drake T.M., Pauley E., Jesudason E.C., Olliaro P., Lim W.S., Gillesen A., Berry C., Lowe D.J., McPeake J. Long Covid in adults discharged from UK Hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO clinical characterisation protocol. Lancet Reg. Health Eur. 2021;8:100186. doi: 10.1016/j.lanepe.2021.100186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100186</ArticleId><ArticleId IdType="pmc">PMC8343377</ArticleId><ArticleId IdType="pubmed">34386785</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D., Munblit D., Pazukhina E., Ricchiuto A., Sinatti D., Zona M., De Matteis A., D&#x2019;Ilario F., Gentili C., Lanni R., et al. Post-COVID condition in adults and children living in the same household in Italy: A prospective cohort study using the ISARIC global follow-up protocol. Front. Pediatr. 2022;10:834875. doi: 10.3389/fped.2022.834875.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2022.834875</ArticleId><ArticleId IdType="pmc">PMC9070551</ArticleId><ArticleId IdType="pubmed">35529336</ArticleId></ArticleIdList></Reference><Reference><Citation>Haunhorst S., Bloch W., Wagner H., Ellert C., Krueger K., Vilser D.C., Finke K., Reuken P., Pletz M.W., Stallmach A., et al. Long COVID: A narrative review of the clinical aftermaths of COVID-19 with a focus on a putative pathophysiology and aspects of physical activity. Oxford Open Immunol. 2022;3:iqac006. doi: 10.1093/oxfimm/iqac006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfimm/iqac006</ArticleId><ArticleId IdType="pmc">PMC9494493</ArticleId><ArticleId IdType="pubmed">36846561</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y., Liu J., Zhang D., Xu Z., Ji J., Wen C. Cytokine storm in COVID-19: The current evidence and treatment strategies. Front. Immunol. 2020;11:1708. doi: 10.3389/fimmu.2020.01708.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01708</ArticleId><ArticleId IdType="pmc">PMC7365923</ArticleId><ArticleId IdType="pubmed">32754163</ArticleId></ArticleIdList></Reference><Reference><Citation>Young S.J. Long-COVID or post-COVID-19 syndrome: Putative pathophysiology, risk factors and treatments. Infect. Dis. 2021;53:737&#x2013;754. doi: 10.1080/23744235.2021.1924397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M., Manoharan L., Elkheir N., Cheng V., Dagens A., Hastie C., O&#x2019;Hara M., Suett J., Dahmash D., Bugaeva P., et al. Characterising Long COVID: A living systematic review. BMJ Glob. Health. 2021;6:e005427. doi: 10.1136/bmjgh-2021-005427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-Acute COVID-19 Syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajjaji N., Lepoutre K., Lakhdar S., B&#xe9;court S., Bellier C., Kaczmarek E., Broyelle A., Giscard S., Lartigau E. 16 Months follow up of patients&#x2019; behavior and mild COVID-19 patterns in a large cohort of cancer patients during the pandemic. Front. Oncol. 2022;12:901426. doi: 10.3389/fonc.2022.901426.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2022.901426</ArticleId><ArticleId IdType="pmc">PMC9209649</ArticleId><ArticleId IdType="pubmed">35747798</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A., Bernabei R., Landi F., Gemelli Against COVID-19 Post-Acute Care Study Group Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M., Cheng V., Manoharan L., Elkheir N., Dagens D., Hastie C., O&#x2019;Hara M., Suett J.C., Dahmash D., Bugaeva P., et al. What are the long-term symptoms and complications of COVID-19: A protocol for a living systematic review. F1000 Res. 2020;9:1455. doi: 10.12688/f1000research.27284.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.27284.1</ArticleId><ArticleId IdType="pmc">PMC8459620</ArticleId><ArticleId IdType="pubmed">34621523</ArticleId></ArticleIdList></Reference><Reference><Citation>Cares-Marambio K., Montenegro-Jimenez Y., Torres-Castro R., Vera-Uribe R., Torralba R., Alsina-Restoy X., Vasconcello-Castillo L., Vilar&#xf3; J. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Chron. Respir. Dis. 2021;18:14799731211002240. doi: 10.1177/14799731211002240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/14799731211002240</ArticleId><ArticleId IdType="pmc">PMC7975482</ArticleId><ArticleId IdType="pubmed">33729021</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W., Hillman T., Playford E.D., Hishmech L. Managing the long-term effects of Covid-19: Summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. doi: 10.1136/bmj.n136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Davido B., Seang S., Tubiana R., de Truchis P. Post&#x2013;COVID-19 chronic symptoms: A postinfectious entity? Clin. Microbiol. Infect. 2020;26:1448&#x2013;1449. doi: 10.1016/j.cmi.2020.07.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.07.028</ArticleId><ArticleId IdType="pmc">PMC7376333</ArticleId><ArticleId IdType="pubmed">32712242</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin S.J., McIvor C., Whyatt G., Adams A., Harvey O., McLean L., Walshaw C., Kemp S., Corrado J., Singh R., et al. Post-discharge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J. Med. Virol. 2020;93:1013&#x2013;1022. doi: 10.1002/jmv.26368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26368</ArticleId><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A.K., Singh R. Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. Diabetes Res. Clin. Pract. 2020;167:108382. doi: 10.1016/j.diabres.2020.108382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2020.108382</ArticleId><ArticleId IdType="pmc">PMC7445123</ArticleId><ArticleId IdType="pubmed">32853686</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Arora A., Sharma P., Anikhindi S., Bansal N., Singla V., Khare S., Srivastava A. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab. Syndr. Clin. Res. Rev. 2020;14:535&#x2013;545. doi: 10.1016/j.dsx.2020.04.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.04.044</ArticleId><ArticleId IdType="pmc">PMC7200339</ArticleId><ArticleId IdType="pubmed">32408118</ArticleId></ArticleIdList></Reference><Reference><Citation>Pranata R., Lim M.A., Huang I., Raharjo S.B., Lukito A.A. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. J. Renin-Angiotensin Aldosterone Syst. 2020;21:1470320320926899. doi: 10.1177/1470320320926899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1470320320926899</ArticleId><ArticleId IdType="pmc">PMC7231906</ArticleId><ArticleId IdType="pubmed">32408793</ArticleId></ArticleIdList></Reference><Reference><Citation>de Almeida-Pititto B., Dualib P.M., Zajdenverg L., Dantas J.R., De Souza F.D., Rodacki M., Bertoluci M.C., Brazilian Diabetes Society Study Group (SBD) Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: A meta-analysis. Diabetol. Metab. Syndr. 2020;12:75. doi: 10.1186/s13098-020-00586-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13098-020-00586-4</ArticleId><ArticleId IdType="pmc">PMC7456786</ArticleId><ArticleId IdType="pubmed">32874207</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Q., Hu B., Zhang Y., Wang H., Zhou X., Hu W., Cheng Y., Yan J., Ping H., Zhou Q. Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China. Int. J. Cardiol. 2020;311:116&#x2013;121. doi: 10.1016/j.ijcard.2020.03.087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2020.03.087</ArticleId><ArticleId IdType="pmc">PMC7141178</ArticleId><ArticleId IdType="pubmed">32291207</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H., Xie L., Liu R., Yang J., Liu F., Wu K., Chen L., Hou W., Feng Y., Zhu C. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. J. Med. Virol. 2020;92:819&#x2013;823. doi: 10.1002/jmv.25809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25809</ArticleId><ArticleId IdType="pmc">PMC7228305</ArticleId><ArticleId IdType="pubmed">32232979</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortini A., Torrigiani A., Sbaragli S., LoForte A., Crociani A., Cecchini P., Bruni G.I., Faraone A. COVID-19: Persistence of symptoms and lung alterations after 3-6 months from hospital discharge. Infection. 2021;49:1007&#x2013;1015. doi: 10.1007/s15010-021-01638-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01638-1</ArticleId><ArticleId IdType="pmc">PMC8179958</ArticleId><ArticleId IdType="pubmed">34091869</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli A., Misuraca C., Bianchi A., Borsa N., Limonta S., Maggiolini S., Bonardi D.R., Corsonello A., Di Rosa M., Soraci L., et al. Long-term changes in pulmonary function among patients surviving to COVID-19 pneumonia. Infection. 2022;50:1019&#x2013;1022. doi: 10.1007/s15010-021-01718-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01718-2</ArticleId><ArticleId IdType="pmc">PMC8517554</ArticleId><ArticleId IdType="pubmed">34652626</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q., Zhong L., Li H., Guo J., Li Y., Hou X., Yang F., Xie Y., Li L., Xing Z. A follow-up study of lung function and chest computed tomography at 6 months after discharge in patients with coronavirus disease 2019. Can. Respir. J. 2021;2021:6692409. doi: 10.1155/2021/6692409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/6692409</ArticleId><ArticleId IdType="pmc">PMC7881736</ArticleId><ArticleId IdType="pubmed">33628349</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro A.O., Cervantes-Bojalil J., Quevedo O.D.J.C., Mart&#xed;nez A.A., Hern&#xe1;ndez-Jim&#xe9;nez C.A., &#xc1;lvarez E.P., Gil A.G., Amaro A.L.P., Lastra O.L.V., Luis B.A.L. Decreased quality of life and spirometric alterations even after mild-moderate COVID-19. Respir. Med. 2021;181:106391. doi: 10.1016/j.rmed.2021.106391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2021.106391</ArticleId><ArticleId IdType="pmc">PMC8044599</ArticleId><ArticleId IdType="pubmed">33865161</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.Y., Chang S.Y., Huang Y.W., Chang S.C. Serology-positive but minimally symptomatic COVID-19 may still cause lung injury and lung function impairment. Int. J. Tuberc. Lung Dis. 2020;24:568&#x2013;569. doi: 10.5588/ijtld.20.0197.</Citation><ArticleIdList><ArticleId IdType="doi">10.5588/ijtld.20.0197</ArticleId><ArticleId IdType="pubmed">32553008</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproston N.R., Ashworth J.J. Role of C-reactive protein at sites of inflammation and infection. Front. Immunol. 2018;9:754. doi: 10.3389/fimmu.2018.00754.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00754</ArticleId><ArticleId IdType="pmc">PMC5908901</ArticleId><ArticleId IdType="pubmed">29706967</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalcante-Silva L.H., Carvalho D.C., de Almeida Lima &#xc9;., Galvao J.G., da Silva J.S., de Sales-Neto J.M., Rodrigues-Mascarenhas S. Neutrophils and COVID-19: The road so far. Inter. Immunopharmacol. 2021;90:107233. doi: 10.1016/j.intimp.2020.107233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.107233</ArticleId><ArticleId IdType="pmc">PMC7703515</ArticleId><ArticleId IdType="pubmed">33290963</ArticleId></ArticleIdList></Reference><Reference><Citation>Caro-Cod&#xf3;n J., Rey J.R., Bu&#xf1;o A., Iniesta A.M., Rosillo S.O., Castrejon-Castrejon S., Rodriguez-Sotelo L., Martinez L.A., Marco I., Merino C., et al. Characterization of NT-proBNP in a large cohort of COVID-19 patients. Eur. J. Heart Fail. 2021;23:456&#x2013;464. doi: 10.1002/ejhf.2095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2095</ArticleId><ArticleId IdType="pmc">PMC8013330</ArticleId><ArticleId IdType="pubmed">33421281</ArticleId></ArticleIdList></Reference><Reference><Citation>Critchley J.A., Carey I.M., Harris T., DeWilde S., Hosking F.J., Cook D.G. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care. 2018;4:2127&#x2013;2135. doi: 10.2337/dc18-0287.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc18-0287</ArticleId><ArticleId IdType="pubmed">30104296</ArticleId></ArticleIdList></Reference><Reference><Citation>Alahmad B., Al-Shammari A.A., Bennakhi A., Al-Mulla F., Ali H. Fasting blood glucose and COVID-19 severity: Nonlinearity matters. Diabetes Care. 2020;43:3113&#x2013;3116. doi: 10.2337/dc20-1941.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-1941</ArticleId><ArticleId IdType="pmc">PMC7770269</ArticleId><ArticleId IdType="pubmed">33051331</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Xie Y., Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259&#x2013;264. doi: 10.1038/s41586-021-03553-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T., Hittle M., Goodman S.N. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: A systematic review. JAMA Netw. Open. 2021;4:e2111417. doi: 10.1001/jamanetworkopen.2021.11417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11417</ArticleId><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M., Braillard O., Alcoba G., Perone S.A., Courvoisier D., Chappuis F., Guessous I. COVID-19 symptoms: Longitudinal evolution and persistence in outpatient settings. Ann. Intern. Med. 2021;174:723&#x2013;725. doi: 10.7326/M20-5926.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-5926</ArticleId><ArticleId IdType="pmc">PMC7741180</ArticleId><ArticleId IdType="pubmed">33284676</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes G.P., Kaplan J.E., Gantz N.M., Komaroff A.L., Schonberger L.B., Straus S.E., Jones J.F., Dubois R.E., Cunningham-Rundles C., Pahwa S., et al. Chronic fatigue syndrome: A working case definition. Ann. Intern. Med. 1988;108:387&#x2013;389. doi: 10.7326/0003-4819-108-3-387.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-108-3-387</ArticleId><ArticleId IdType="pubmed">2829679</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickie I., Davenport T., Wakefield D., Vollmer-Conna U., Cameron B., Vernon S.D., Reeves W.C., Lloyd A. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: Prospective cohort study. BMJ. 2006;333:575. doi: 10.1136/bmj.38933.585764.AE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.38933.585764.AE</ArticleId><ArticleId IdType="pmc">PMC1569956</ArticleId><ArticleId IdType="pubmed">16950834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner A.M., Robinson D.A., Yang L., Williams C.F., Newman L.M., Breen J.J., Eisinger R.W., Schneider J.S., Adimora A.A., Erbelding E.J. Toward understanding COVID-19 recovery: National Institutes of Health workshop on postacute COVID-19. Ann. Intern. Med. 2021;174:999&#x2013;1003. doi: 10.7326/M21-1043.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-1043</ArticleId><ArticleId IdType="pmc">PMC8025940</ArticleId><ArticleId IdType="pubmed">33780290</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik P.K., Moore B.B. Viral infection and aging as cofactors for the development of pulmonary fibrosis. Expert Rev. Respir. Med. 2010;4:759&#x2013;771. doi: 10.1586/ers.10.73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/ers.10.73</ArticleId><ArticleId IdType="pmc">PMC3028433</ArticleId><ArticleId IdType="pubmed">21128751</ArticleId></ArticleIdList></Reference><Reference><Citation>Abelmann W.H. Virus and the heart. Circulation. 1971;44:950&#x2013;956. doi: 10.1161/01.CIR.44.5.950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.44.5.950</ArticleId><ArticleId IdType="pubmed">5115086</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechowicz K., Drozdzal S., Machaj F., Rosik J., Szostak B., Zegan-Bara&#x144;ska M., Biernawska J., Dabrowski W., Rotter I., Kotfis K. COVID-19: The potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection. J. Clin. Med. 2020;9:1917. doi: 10.3390/jcm9061917.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9061917</ArticleId><ArticleId IdType="pmc">PMC7356800</ArticleId><ArticleId IdType="pubmed">32575380</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali R.M.M., Ghonimy M.B.I. Post-COVID-19 pneumonia lung fibrosis: A worrisome sequelae in surviving patients. Egypt. J. Radiol. Nucl. Med. 2021;52:101. doi: 10.1186/s43055-021-00484-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43055-021-00484-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Bose R., McCarthy J. Direct SARS-CoV-2 infection of the heart potentiates the cardiovascular sequelae of COVID-19. Drug Discov. Today. 2020;25:1559&#x2013;1560. doi: 10.1016/j.drudis.2020.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2020.06.021</ArticleId><ArticleId IdType="pmc">PMC7313487</ArticleId><ArticleId IdType="pubmed">32592868</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalysnyk L., Hernandez-Medina M., Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: Evidence from a systematic review of the literature. Diabetes Obes. Metab. 2010;12:288&#x2013;298. doi: 10.1111/j.1463-1326.2009.01160.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1463-1326.2009.01160.x</ArticleId><ArticleId IdType="pubmed">20380649</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365:217&#x2013;223. doi: 10.1016/S0140-6736(05)17741-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)17741-1</ArticleId><ArticleId IdType="pubmed">15652604</ArticleId></ArticleIdList></Reference><Reference><Citation>Forouzanfar M.H., Liu P., Roth G.A., Ng M., Biryukov S., Marczak L., Alexander L., Estep K., Abate K.H., Akinyemiju T.F., et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990&#x2013;2015. JAMA. 2017;317:165&#x2013;182. doi: 10.1001/jama.2016.19043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.19043</ArticleId><ArticleId IdType="pubmed">28097354</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X., Shi L., Wang Y., Xiao W., Duan G., Yang H. The association of hypertension with the severity and mortality of COVID-19 patients: Evidence based on adjusted effect estimates. J. Infect. 2020;81:e44&#x2013;e47. doi: 10.1016/j.jinf.2020.06.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.06.060</ArticleId><ArticleId IdType="pmc">PMC7315979</ArticleId><ArticleId IdType="pubmed">32593655</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhur M.S., Elijovich F., Alexander M.R., Pitzer A., Ishimwe J., Van Beusecum J.P., Patrick D.M., Smart C.D., Kleyman T.R., Kingery J., et al. Hypertension. Do inflammation and immunity hold the key to solving this epidemic? Circ. Res. 2021;128:908&#x2013;933. doi: 10.1161/CIRCRESAHA.121.318052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.121.318052</ArticleId><ArticleId IdType="pmc">PMC8023750</ArticleId><ArticleId IdType="pubmed">33793336</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao C., Cai Y., Zhang K., Zhou L., Zhang Y., Zhang X., Li Q., Li W., Yang S., Zhao X., et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: A retrospective observational study. Eur. Heart J. 2020;41:2058&#x2013;2066. doi: 10.1093/eurheartj/ehaa433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa433</ArticleId><ArticleId IdType="pmc">PMC7314067</ArticleId><ArticleId IdType="pubmed">32498076</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisti N., Valente S., Mandoli G.E., Santoro C., Sciaccaluga C., Franchi F., Cameli P., Mondillo S., Cameli M. COVID-19 in patients with heart failure: The new and the old epidemic. Postgrad. Med. J. 2021;97:175&#x2013;179. doi: 10.1136/postgradmedj-2020-138080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2020-138080</ArticleId><ArticleId IdType="pmc">PMC10016991</ArticleId><ArticleId IdType="pubmed">32732260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics. 2014;6:748&#x2013;773. doi: 10.1039/C3MT00347G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C3MT00347G</ArticleId><ArticleId IdType="pubmed">24549403</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D., Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin. Immunopathol. 2012;34:43&#x2013;62. doi: 10.1007/s00281-011-0290-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-011-0290-8</ArticleId><ArticleId IdType="pubmed">22037947</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar R., Fish R.J., Casini A., Neerman-Arbez M. Fibrin (ogen) in human disease: Both friend and foe. Haematologica. 2020;105:284&#x2013;296. doi: 10.3324/haematol.2019.236901.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2019.236901</ArticleId><ArticleId IdType="pmc">PMC7012490</ArticleId><ArticleId IdType="pubmed">31949010</ArticleId></ArticleIdList></Reference><Reference><Citation>Len P., Iskakova G., Sautbayeva Z., Kussanova A., Taeukelova A.T., Sugralimova M.M., Dautbayeva A.S., Abdieva M.M., Ponomarev E.D., Tikhonov A., et al. Meta-analysis and systematic review of coagulation disbalances in COVID-19: 41 studies and 17,601 patients. Front. Cardiovasc. Med. 2022;9:794092. doi: 10.3389/fcvm.2022.794092.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.794092</ArticleId><ArticleId IdType="pmc">PMC8962835</ArticleId><ArticleId IdType="pubmed">35360017</ArticleId></ArticleIdList></Reference><Reference><Citation>Long W., Yang J., Li Z., Li J., Chen S., Chen D., Wang S., Li Q., Hu D., Huang J., et al. Abnormal fibrinogen level as a prognostic Indicator in coronavirus disease patients: A retrospective cohort study. Front. Med. 2021;8:687220. doi: 10.3389/fmed.2021.687220.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.687220</ArticleId><ArticleId IdType="pmc">PMC8236504</ArticleId><ArticleId IdType="pubmed">34195213</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartari C.J., Milani G., Salvetti F., Marchetti M., Russo L., Vignoli A., Vitali M., Schieppati F., Ravasio G., Castellani L., et al. Post-Covid-19 hemostatic characteristics of convalescent patients: The Bergamo Experience. Blood. 2021;138:1054. doi: 10.1182/blood-2021-153611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2021-153611</ArticleId></ArticleIdList></Reference><Reference><Citation>Medranda G.A., Fazlalizadeh H., Case B.C., Yerasi C., Zhang C., Rapaport H., Shea C., Weintraub W.S., Waksman R. Implications of left ventricular function on short-term outcomes in COVID-19 patients with myocardial injury. Cardiovasc. Revasc. Med. 2021;29:45&#x2013;49. doi: 10.1016/j.carrev.2021.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carrev.2021.03.028</ArticleId><ArticleId IdType="pmc">PMC8023790</ArticleId><ArticleId IdType="pubmed">34049818</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou M., Wong C., Un K., Lau Y., Lee J., Tam F., Lau Y.-M., Lai W.-H., Tam A.R., Lam Y.-Y., et al. Cardiovascular sequalae in uncomplicated COVID-19 survivors. PLoS ONE. 2021;16:e0246732. doi: 10.1371/journal.pone.0246732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246732</ArticleId><ArticleId IdType="pmc">PMC7877588</ArticleId><ArticleId IdType="pubmed">33571321</ArticleId></ArticleIdList></Reference><Reference><Citation>Satterfield B.A., Bhatt D.L., Gersh B.J. Cardiac involvement in the long-term applications of COVID-19. Nat. Rev. Cardiol. 2022;19:332&#x2013;341. doi: 10.1038/s41569-021-00631-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-021-00631-3</ArticleId><ArticleId IdType="pmc">PMC8532434</ArticleId><ArticleId IdType="pubmed">34686843</ArticleId></ArticleIdList></Reference><Reference><Citation>Tudoran C., Tudoran M., Cut T.G., Lazureanu V.E., Oancea C., Marinescu A.R., Pescariu R.A., Pop G.N., Bende F. Evolution of echocardiographic abnormalities identified in previously healthy individuals recovering from COVID-19. J. Pers. Med. 2022;12:46. doi: 10.3390/jpm12010046.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12010046</ArticleId><ArticleId IdType="pmc">PMC8778114</ArticleId><ArticleId IdType="pubmed">35055360</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammad M., Emin M., Bhutta A., Gul E.H., Voorhees E., Afzal M.R. Cardiac arrhythmias associated with COVID-19 infection: State of the art review. Expert Rev. Cardiovasc. Ther. 2021;19:881&#x2013;889. doi: 10.1080/14779072.2021.1997589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14779072.2021.1997589</ArticleId><ArticleId IdType="pmc">PMC8607535</ArticleId><ArticleId IdType="pubmed">34702128</ArticleId></ArticleIdList></Reference><Reference><Citation>Suthahar N., Meijers W.C., Sillj&#xe9; H.H., de Boer R.A. From inflammation to fibrosis&#x2014;Molecular and cellular mechanisms of myocardial tissue remodelling and perspectives on differential treatment opportunities. Curr. Heart Fail. Rep. 2017;14:235&#x2013;250. doi: 10.1007/s11897-017-0343-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11897-017-0343-y</ArticleId><ArticleId IdType="pmc">PMC5527069</ArticleId><ArticleId IdType="pubmed">28707261</ArticleId></ArticleIdList></Reference><Reference><Citation>Raafs A.G., Verdonschot J.A., Henkens M.T., Adriaans B.P., Wang P., Derks K., Hamid M.A.A., Knackstedt C., Empel V.P., D&#xed;ez J., et al. The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy&#x2014;A multilevel assessment of myocardial fibrosis in dilated cardiomyopathy. Eur. J. Heart Fail. 2021;23:933&#x2013;944. doi: 10.1002/ejhf.2201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2201</ArticleId><ArticleId IdType="pmc">PMC8362085</ArticleId><ArticleId IdType="pubmed">33928704</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer R.A., De Keulenaer G., Bauersachs J., Brutsaert D., Cleland J.G., Diez J., Du X., Ford P., Heinzel F.R., Lipson K.E., et al. Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. Eur. J. Heart Fail. 2019;21:272&#x2013;285. doi: 10.1002/ejhf.1406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.1406</ArticleId><ArticleId IdType="pmc">PMC6607480</ArticleId><ArticleId IdType="pubmed">30714667</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandler M. Is the lung a &#x2018;target organ&#x2019; in diabetes mellitus? Arch. Intern. Med. 1990;150:1385&#x2013;1388. doi: 10.1001/archinte.1990.00390190051006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.1990.00390190051006</ArticleId><ArticleId IdType="pubmed">2196023</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia C.C., Raskin P. The diabetic lung: Relevance of alveolar microangiopathy for the use of inhaled insulin. Am. J. Med. 2005;118:205&#x2013;211. doi: 10.1016/j.amjmed.2004.09.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2004.09.019</ArticleId><ArticleId IdType="pubmed">15745714</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Xue Q., Miao L., Cai L. Pulmonary fibrosis: A possible diabetic complication. Diabetes/Metab. Res. Rev. 2011;27:311&#x2013;317. doi: 10.1002/dmrr.1175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.1175</ArticleId><ArticleId IdType="pubmed">21309056</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J.K., Feng Y., Yuan M.Y., Yuan S.Y., Fu H.J., Wu B.Y., Sun G.Z., Yang G.R., Zhang X.L., Wang L., et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet. Med. 2006;23:623&#x2013;628. doi: 10.1111/j.1464-5491.2006.01861.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-5491.2006.01861.x</ArticleId><ArticleId IdType="pubmed">16759303</ArticleId></ArticleIdList></Reference><Reference><Citation>Alraddadi B., Watson J.T., Almarashi A., Abedi G.R., Turkistani A., Sadran M., Housa A., AlMazroa M.A., Alraihan N., Banjar A., et al. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg. Infect. Dis. 2016;22:49&#x2013;55. doi: 10.3201/eid2201.151340.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2201.151340</ArticleId><ArticleId IdType="pmc">PMC4696714</ArticleId><ArticleId IdType="pubmed">26692185</ArticleId></ArticleIdList></Reference><Reference><Citation>Shim H., Hanm X., Jiangm N., Caom Y., Alwalid O., Gu J., Fan Y., Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infect. Dis. 2020;20:425&#x2013;434. doi: 10.1016/S1473-3099(20)30086-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30086-4</ArticleId><ArticleId IdType="pmc">PMC7159053</ArticleId><ArticleId IdType="pubmed">32105637</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang A.T., Garcia-Carreras B., Hitchings M.D., Yang B., Katzelnick L.C., Rattigan S.M., Borgert B.A., Moreno C.A., Solomon B.D., Trimmer-Smith L., et al. A systematic review of antibody mediated immunity to coronaviruses: Kinetics, correlates of protection, and association with severity. Nat. Commun. 2020;11:4704. doi: 10.1038/s41467-020-18450-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18450-4</ArticleId><ArticleId IdType="pmc">PMC7499300</ArticleId><ArticleId IdType="pubmed">32943637</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallon P.W., Tinago W., Leon A.G., McCann K., Kenny G., McGettrick P., Green S., Inzitari R., Cottere A.G., Feeney E.R., et al. Dynamic change and clinical relevance of postinfectious SARS-CoV-2 antibody responses. Open Forum Infect. Dis. 2021;8:ofab122. doi: 10.1093/ofid/ofab122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab122</ArticleId><ArticleId IdType="pmc">PMC8083770</ArticleId><ArticleId IdType="pubmed">34377721</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;t&#x11b;p&#xe1;nek L., Jano&#x161;&#xed;kov&#xe1; M., &#x160;t&#x11b;p&#xe1;nek L., Nakl&#xe1;dalov&#xe1; M., Borikov&#xe1; A. The kinetics and predictors of anti-SARS-CoV-2 antibodies up to 8 months after symptomatic COVID-19: A Czech cross-sectional study. J. Med. Virol. 2022;94:3731&#x2013;3738. doi: 10.1002/jmv.27784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27784</ArticleId><ArticleId IdType="pmc">PMC9088611</ArticleId><ArticleId IdType="pubmed">35419860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bichara C.D., Amoras E.S., Vaz G.L., Bichara C.N., Amaral I.P., Vallinoto A.C. Persistence of Anti-SARS-CoV-2 IgM antibody up to 8 Months post-COVID-19. Case Rep. Clin. Med. 2021;10:227&#x2013;231. doi: 10.4236/crcm.2021.109029.</Citation><ArticleIdList><ArticleId IdType="doi">10.4236/crcm.2021.109029</ArticleId></ArticleIdList></Reference><Reference><Citation>Hills S.L., Van Keulen A., Feser J., Panella A., Letson G.W., Staples J.E., Marfin A.A., Brault A.C. Persistence of IgM antibodies after vaccination with live attenuated Japanese encephalitis vaccine. Amer. J. Trop. Med. Hyg. 2021;104:576&#x2013;579. doi: 10.4269/ajtmh.20-1132.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.20-1132</ArticleId><ArticleId IdType="pmc">PMC7866339</ArticleId><ArticleId IdType="pubmed">33236716</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao H.W., Ashcavai M., Redeker A.G. The persistence of hepatitis A IgM antibody after acute clinical hepatitis A. Hepatology. 1984;4:933&#x2013;936. doi: 10.1002/hep.1840040525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.1840040525</ArticleId><ArticleId IdType="pubmed">6090293</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien Y.-W., Liu Z.-H., Tseng F.-C., Ho T.-C., Guo H.-R., Ko N.-Y., Ko W.-C., Perng G.C. Prolonged persistence of IgM against dengue virus detected by commonly used commercial assays. BMC Infect. Dis. 2018;18:156. doi: 10.1186/s12879-018-3058-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-018-3058-0</ArticleId><ArticleId IdType="pmc">PMC5880084</ArticleId><ArticleId IdType="pubmed">29609533</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin I., Martin S.W., Fischer M., Chambers T.V., Kosoy O.L., Goldberg C., Falise A., Villamil V., Ponomareva O., Gillis L.D., et al. Zika virus IgM 25 months after symptom onset, Miami-Dade county, Florida, USA. Emerg. Infect. Dis. 2019;25:2264&#x2013;2265. doi: 10.3201/eid2512.191022.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2512.191022</ArticleId><ArticleId IdType="pmc">PMC6874245</ArticleId><ArticleId IdType="pubmed">31742511</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibney K.B., Edupuganti S., Panella A.J., Kosoy O.I., Delorey M.J., Lanciotti R.S., Mulligan M.J., Fischer M., Staples J.E. Detection of anti-yellow fever virus immunoglobulin M antibodies at 3&#x2013;4 years following yellow fever vaccination. Am. J. Trop. Med. Hyg. 2012;87:1112&#x2013;1115. doi: 10.4269/ajtmh.2012.12-0182.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.2012.12-0182</ArticleId><ArticleId IdType="pmc">PMC3516084</ArticleId><ArticleId IdType="pubmed">23109371</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapoor H., Signs K., Somsel P., Downes F.P., Clark P.A., Massey J.P. Persistence of West Nile Virus (WNV) IgM antibodies in cerebrospinal fluid from patients with CNS disease. J. Clin. Virol. 2004;31:289&#x2013;291. doi: 10.1016/j.jcv.2004.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2004.05.017</ArticleId><ArticleId IdType="pubmed">15494271</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehrig J.T., Nash D., Maldin B., Labowitz A., Martin D.A., Lanciotti R.S., Campbell G.L. Persistence of virus-reactive serum immunoglobulin M antibody in confirmed West Nile virus encephalitis cases. Emerg. Infect. Dis. 2003;9:376&#x2013;379. doi: 10.3201/eid0903.020531.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0903.020531</ArticleId><ArticleId IdType="pmc">PMC2958550</ArticleId><ArticleId IdType="pubmed">12643836</ArticleId></ArticleIdList></Reference><Reference><Citation>Papa A., Xanthopoulou K., Gewehr S., Mourelatos S. Detection of West Nile virus lineage 2 in mosquitoes during a human outbreak in Greece. Clin. Microbiol. Infect. 2011;17:1176&#x2013;1180. doi: 10.1111/j.1469-0691.2010.03438.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2010.03438.x</ArticleId><ArticleId IdType="pubmed">21781205</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray K.O., Garcia M.N., Yan C., Gorchakov R. Persistence of detectable immunoglobulin M antibodies up to 8 years after infection with West Nile virus. Amer. J. Trop. Med. Hyg. 2013;89:996&#x2013;1000. doi: 10.4269/ajtmh.13-0232.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.13-0232</ArticleId><ArticleId IdType="pmc">PMC3820351</ArticleId><ArticleId IdType="pubmed">24062481</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreye J., Reincke S.M., Pr&#xfc;ss H. Do cross-reactive antibodies cause neuropathology in COVID-19? Nat. Rev. Immunol. 2020;20:645&#x2013;646. doi: 10.1038/s41577-020-00458-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00458-y</ArticleId><ArticleId IdType="pmc">PMC7537977</ArticleId><ArticleId IdType="pubmed">33024283</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A., Monro J., Lanzisera F., Sadeghi H. Serological cross-reactivity between viruses and their contribution to autoimmunity. Autoimmun. Rev. 2021;20:102840. doi: 10.1016/j.autrev.2021.102840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102840</ArticleId><ArticleId IdType="pubmed">33971342</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>